Cytokinetics (CYTK) revenue breakdown
By product, License and Milestone Revenues is the largest at 90% of fiscal 2025 revenue, growing 95% a year over 5 years.
Revenue by product
Fiscal years, as Cytokinetics reports them in its 10-K filings; fiscal 2025 total $88M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| License and Milestone Revenues | $3M | $5M | $1M | $4M | $15M | $79M | 90% |
| Collaboration Revenues | $17M | $11M | $7M | $4M | $3M | $9M | 10% |
| Realization of Revenue Participation Right Purchase Agreement | — | — | $87M | — | — | — | — |
| License Revenues | — | $55M | — | — | — | — | — |
| License Revenues | $37M | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CYTK.
Open CYTK in InvestinglyQuestions
Where does Cytokinetics make its money?
In fiscal 2025, by product: License and Milestone Revenues $79M, Collaboration Revenues $9M.
From Cytokinetics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.